# Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)

> **NCT00110851** · PHASE2 · COMPLETED · sponsor: **Wellstat Therapeutics** · enrollment: 90 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** rosiglitazone
- **DRUG:** metformin
- **DRUG:** PN2034

## Key facts

- **NCT ID:** NCT00110851
- **Lead sponsor:** Wellstat Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** —
- **Final completion:** 2007-08
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2007-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00110851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00110851, "Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00110851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*